Michael Gallo

Michael Gallo is a distinguished leader in the biotherapeutics field, currently serving as the Founder of Tentarix Biotherapeutics, Inc. since July 2020. Gallo also holds the positions of President at Innovative Targeting Solutions Inc. since June 2008 and Co-Founder of A2 Biotherapeutics, Inc. since January 2018. Previously, Gallo was the Vice President and Executive Director at Amgen British Columbia from April 2006 to August 2007, where oversight of a dedicated research group specializing in therapeutic antibodies took place. Prior experience includes serving as Vice President of Research and Site-head at Abgenix Inc. from 2001 to 2006.